Osemitamab (FUT8-KO)

Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study[1][2].

12352203

Gap Junction Protein

Cytoskeleton

Cancer-programmed cell death

Cancer

[Osemitamab(FUT8-KO)]

[1]Shen L, et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002) [J]. 2023.|[2]Park Soon Jae, et al. Pharmaceutical composition comprising human hyaluronidase PH20 variants for drug delivery system via subcutaneous injection. World Intellectual Property Organization, WO2023075506 A1. 2023-05-04.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P9991A/

Inhibitory Antibodies

No Development Reported